Open AccessThe prospects for using bemiparin in prophylaxis and treatment of thromboses in oncology
Author(s) -
О. B. Сомонова,
А. Л. Елизарова,
Ю А Нестерова,
Natalia N Borisenko,
У. А. Корнюшенко
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-10-103-106
Subject(s) - low molecular weight heparin , medicine , clinical trial , heparin , pharmacology , oncology
Oncological patients have a high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and is one of the leading causes of death. Low molecular weight heparins are the main drugs for the prevention and treatment of thrombotic complications in cancer patients. Zibor (bemiparin) is a second-generation low-molecular-weight heparin (LMWH) that has the lowest molecular weight (3600 Dalton), a half-life increased to 5.3 hours and the highest anti-Factor Xa activity ratio (8:1). In clinical trials, bemiparin has demonstrated high efficacy and safety for prophylaxis and treatment of thromboembolic complications.